Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia.
|
11587205 |
2001 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutually exclusive oncogenic rearrangements may delineate specific T-cell acute lymphoblastic leukaemia (T-ALL) subgroups, and so far at least 4 molecular-cytogenetic subgroups have been identified, i.e. the TAL/LMO, the TLX1/HOX11, the TLX3/HOX11L2 and the HOXA subgroups.
|
21112032 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
|
17308084 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic analysis of a pediatric T-cell acute lymphoblastic leukemia (ALL) cell line (HPB-ALL) revealed the cryptic t(5;14)(q35;q32.2), recently found in 15-20% pediatric T-ALL patients, with 5q35 and 14q32.2 breakpoints at 5'-HOX11L2 and 3'-BCL11B, respectively.
|
12661009 |
2003 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
This study provides a genome-wide overview of copy number changes in TLX3 rearranged T-ALL and offers great new challenges for the identification of new target genes that may play a role in the pathogenesis of T-ALL.
|
18185524 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most common recurrent cytogenetic abnormalities in T-lymphoblastic leukemia (T-acute lymphoblastic leukemia [T-ALL]) involve T-cell receptor (TCR) loci and a variety of partner genes, including HOX11, HOX11L2, MYC, and TAL1.
|
22563559 |
2012 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We did not identify cases with a t(5;14)(q35;q32) involving CSX, but we did identify 5 cases of t(5;14) involving HOX11L2 out of 32 T-ALL cases studied; in each case the 14q32 breakpoint was found to be centromeric to the IGH region.
|
15194534 |
2004 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These cases generally lacked overexpression of the TAL1, HOX11, HOX11L2, or the HOXA cluster genes, which have been used to define separate molecular pathways leading to T-ALL.
|
20124220 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL7R mutations induce a gene expression profile partially resembling that provoked by IL-7 and are enriched in the T-ALL subgroup comprising TLX3 rearranged and HOXA deregulated cases.
|
21892159 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the prognostic effect of the expression levels of eight oncogenic transcription factors--TLX1 (HOX11), TLX3 (HOX11L2), TAL1, TAL2, LYL1, OLIG2 (BHLHB1), LMO1, and LMO2--in 52 adults with T-cell acute lymphoblastic leukaemia.
|
14975618 |
2004 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This was associated with an inferior OS for HOX11L2 T-ALLs (13% vs 47% in HOX11L2-T-ALLs; P = .009).
|
15637138 |
2005 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although molecular disease was frequently present after a 4-drug induction therapy, final treatment outcome was excellent indicating that TLX3+ T-ALL cases may benefit from a BFM-type of ALL therapy with early and late re-intensification elements.
|
19821827 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study provides a genome-wide overview of copy number changes in TLX3 rearranged T-ALL and offers great new challenges for the identification of new target genes that may play a role in the pathogenesis of T-ALL.
|
18185524 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TLX1- or TLX3-deregulated T-cell acute lymphoblastic leukemias (T-ALL; TLX1/3<sup>+</sup>) share an immature cortical phenotype and similar transcriptional signatures.
|
30659025 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with T-cell acute lymphoblastic leukemia positive for TLX3 had a poorer survival compared to those with T-ALL negative for TLX3 (overall survival: 45+/-11% vs. 57+/-5%, p=0.049).
|
18835836 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HOX11 and the closely related HOX11L2 genes play a key role in T-ALL.
|
12750702 |
2003 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Three members of the NK-like subfamily of homeobox genes (NKLs), TLX1, TLX3 and NKX2-5, are implicated in T-cell acute lymphoblastic leukemia (T-ALL).
|
19835636 |
2009 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis.
|
12130513 |
2002 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SIL-TAL1 fusion gene and the ectopic expression of HOX11L2 are common molecular abnormalities in T-cell acute lymphoblastic leukemia (T-ALL).
|
19562638 |
2009 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results also show that HOX11L2 expression essentially occurs as a result of a 5q35 rearrangement, but is not associated with another identified T-ALL specific recurrent genetic abnormality, such as SIL-TAL fusion or HOX11 expression.
|
12970786 |
2003 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The full characterization of the TLX3 transcription regulation will ultimately provide crucial elements to define the involvement of this gene in T-cell acute lymphocytic leukemia development.
|
16966433 |
2006 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study further underscores that TLX3 expression in T-ALL is strongly associated with the presence of genomic rearrangements.
|
15334547 |
2004 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
NKX2-5, SIL/TAL and TLX3/HOX11L2 expression in Egyptian pediatric T-cell acute lymphoblastic leukemia.
|
24571118 |
2016 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that TLX3 expression is not an indicator for the prognosis of pediatric T-ALL.
|
24997618 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia.
|
29296717 |
2017 |